linjc16/ctgov huggingface dataset:
A1c Discordance in Diabetes Patients

Study Overview
=================
Brief Summary
-----------------
HbA1c is used as a gold standard to see whether patients have optimal glycemic control. Today, many physicians rely solely on HbA1c to change medication. However, there is a select group of patients that have low average glucose levels but high HbA1c levels. The investigators believe that these patients are fast glycators meaning that they incorporate sugar into their hemoglobin faster than normal. The investigators want to determine whether these patients are fast glycators.

Official Title
-----------------
Differences in Hemoglobin Glycation Rate in Diabete Mellitus Patients

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Other: Fast Glycator
* Other: Control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with diabetes Patients who test their sugar levels at least 3 times daily Recorded diary of sugar levels for the past month Willingness to have blood drawn Willingness to allow their blood sugar diary to be photocopied Estimated average glucose as derived from A1c is ≥ 4 mmol from measured glucose from self-monitoring blood glucose testing Exclusion Criteria: Patient with medical conditions that may affect their study participation or results will be excluded. Patients who are anemic Renal insufficient with a serum creatinine level > 200 μmol/L

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Fast Glycator<br>The subjects enrolled in this study will have a fructosamine test and blood drawn to see whether they are fast glycators | Other: Fast Glycator<br>* The subjects enrolled in this study will have a fructosamine test and blood drawn to see whether they are fast glycators<br>|
| Active Comparator: Control<br>These patients will have their blood drawn to know what the normal glycation rate is in diabetic patients | Other: Control<br>* These patients will have their blood drawn to know what the normal glycation rate is in diabetic patients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary endpoint is to see whether they are fast glycators |  | One Week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| A secondary endpoint includes adverse events such as unplanned hospitalizations for any cause that last more than 24 hours |  | One Week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetes Mellitus, HbA1c, Glycation Rate, Fructosamine
Polish Survey on the Efficacy of the Hypercholesterolemia Treatment

Study Overview
=================
Brief Summary
-----------------
The purpose of the survey is to evaluate the efficacy of treatment of hypercholesterolemia in Polish patients who are currently on lipid- lowering pharmacological therapy . Efficient treatment is defined as achievement of the LDL cholesterol level goals according to the European Society of Cardiology 2007 guidlines.

Official Title
-----------------
Centralized Pan-European Survey on the Undertreatment of Hypercholesterolemia. Polish Survey on the Efficacy of the Hypercholesterolemia Treatment

Conditions
-----------------
Hypercholesterolemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients on lipid lowering drug treatment Lipid lowering drug treatment lasting at least 3 months No lipid lowering drug/dose change for a minimum 6 weeks prior to enrolment to the study Exclusion Criteria: Lack of patient's signed informed consent form Lack of the blood sample taken for lipid profile and glucose within 10 days before or after assessment of the patient

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Patients with hypercholesterolemia on lipid lowering pharmacological treatment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| establish the proportion of patients on lipid lowering pharmacological treatment reaching the LDL-C goals according to ESC 2007 guidelines in general. |  | whole study procedure takes place during the one, single patient's visit | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| establish the proportion of patients on lipid lowering pharmacological treatment in primary prevention, reaching the LDL-C goals according to ESC 2007 guidelines for this sub-population |  | whole study procedure takes place during the one, single patient's visit | 
| establish the proportion of patients on lipid lowering pharmacological treatment in secondary prevention, reaching the LDL-C goals according to ESC 2007 guidelines for this sub-population |  | whole study procedure takes place during the one, single patient's visit | 
| identify determinants (patient and physician characteristics) for undertreatment of hypercholesterolemia. |  | whole study procedure takes place during the one, single patient's visit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hypercholesterolemia, low density lipoprotein, undertreatment of hypercholesterolemia
OCT-angiography as a Pronostic Marker for Visual Impairment in Patients Undergoing Neurosurgery for Compressive Macroadenoma : a Prospective Study.

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to assess accurancy of OCT angiography as a pronostic marker for patients undergoing neurosurgery for compressiver macroadenoma as compared with visual acuity, visual field and OCT.

Official Title
-----------------
OCT-angiography as a Pronostic Marker for Visual Impairment in Patients Undergoing Neurosurgery for Compressive Macroadenoma : a Prospective Study.

Conditions
-----------------
Pituitary Adenoma

Intervention / Treatment
-----------------
* Procedure: Neurosurgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pituitary compressive adenoma (for experimental group) pituitary non compressive adenoma Exclusion Criteria: retinian disease amblyopia parkinson disease pregnant woman

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Non compressive adenoma<br>Optical Coherence Tomography Angiography without surgery | |
| Experimental: Compressive adenoma<br>Optical Coherence Tomography Angiography before and after neurosurgery | Procedure: Neurosurgery<br>* adenoma removal<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change of middle deviation | visual field evolution assessed by Middle deviation | before surgery (= inclusion), 4 months after surgery and 10 months after surgery | 
| Change of visual function index | visual field evolution assessed by visual function index | before surgery (= inclusion), 4 months after surgery and 10 months after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
macroadenoma
Identification of Desaturation Episodes by Means of Continuous Measurement of Oxygen Saturation During Hemodialysis

Study Overview
=================
Brief Summary
-----------------
The clinical diagnosis of sleep apnea is difficult among ESRD patients since the characteristic clinical features of sleep apnea may be absent and since sleep-related symptoms, such as fatigue and sleepiness, may be attributed to kidney failure. However, the evaluation of patients with possible sleep apnea is the same among ESRD patients as in the general population.

Official Title
-----------------
Identification of Desaturation Episodes by Means of Continuous Measurement of Oxygen Saturation During Hemodialysis

Conditions
-----------------
ESRD, Sleep Apnea, Oxygen Deficiency

Intervention / Treatment
-----------------
* Other: Observational


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥18 years and able to give written informed consent to the study On chronic hemodialysis for ≥ 90 days at time of enrollment Ability to read Consent to have video recording taken during study visit Exclusion Criteria: Subjects with cognitive impairment to consent Sickle cell anemia Prescription of nasal oxygen Simultaneous participation in another clinical trial that may affect breathing frequency/patterns, blood oxygenation, sleep/wake cycle or other parameters related to the outcomes of interest to this study Use of a breathing device, e.g. CPAP Central venous catheter used as vascular access for hemodialysis Artificial fingernails (may disturb the measurement of the WatchPAT) Use of one of the following medications: alpha blockers, short acting nitrates (less than 3 hours before the study). Permanent pacemaker Sustained non-sinus cardiac arrhythmias.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ESRD Patients<br>The following inclusion criteria must be met for each subject. Age ≥18 years and able to give written informed consent to the study On chronic hemodialysis for ≥ 90 days at time of enrollment Ability to read Consent to have video recording taken during study visit | Other: Observational<br>* Collect anthropomorphic, WatchPAT, Crit-line Monitor measurements as well as sleep questionnaires and video records<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identifying Intradialytis desaturation episodes | • To determine the sensitivity and specificity of the CLM for identifying intradialytic desaturation episodes, using the WatchPAT device as the reference method. | 1 week |
Diaphragm Movement During Its Postural Function

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to describe the movement of the diaphragm during postural activation of the trunk muscles in comparison with tidal breathing.

Detailed Description
-----------------
Diaphragm movement will be measured by m-mode ultrasonography in a standing position. 30-35 healthy subjects will participate in the study. The movement of the diaphragm will be measured during tidal breathing then, during holding a load corresponding to 20% of the subject´s body weight and finally, during voluntary contraction of the trunk muscles. Trunk muscles contraction will be measured by a special device with pressure sensors placed on a trunk surface. Breathing activity will be measured by spirometry.

Official Title
-----------------
Analysis of Diaphragm Movement During Its Postural Function Using M-mode Ultrasonography in Conjunction With Spirometry

Conditions
-----------------
Diaphragm Movement

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed informed consent form Able to comply with the study protocol, in the investigator's judgment Aged 20-40 years, inclusive Healthy as determined by the Investigator based on medical history, physical examination, vital signs and neurological examination Waist-to-height ratio < 0,59 Exclusion Criteria: Low back pain (acute or chronic) Previous abdominal or spine surgery Acute or chronic respiratory or musculoskeletal disorder Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks before initiation of the study Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diaphragm movement | Distance of the diaphragm from the ultrasound transducer in millimeters during tidal breathing, during holding a load, and during voluntary contraction of the trunk muscles | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tidal volume | Tidal volume in litres measured by spirometry during tidal breathing, during holding a load, and during voluntary contraction of the trunk muscles | 6 months | 
| Activity of the trunk muscles | Relative pressure in kilopascals generated by the trunk muscles during tidal breathing, during holding a load, and during voluntary contraction of these muscles | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diaphragmatic motion, m-mode ultrasonography, postural function
Comparison Between hCG and GnRH Agonist for Ovulation Induction in Patients With High Response to IVF Drugs

Study Overview
=================
Brief Summary
-----------------
hCG and GnRH agonist can be used to induce final oocyte maturation and ovulation in IVF cycles. These two approaches will be compared in this study in terms of pregnancy rates and embryological data using patients with hyper-response to IVF drugs.

Detailed Description
-----------------
hCG is commonly used for the substitution of the endogenous LH surge to induce oocyte maturation and ovulation induction in ovarian hyperstimulation protocols for in vitro fertilization (IVF). However, hCG is related to the occurrence of the ovarian hyperstimulation syndrome (OHSS), a potentially life-threatening complication and hyper-responding patients are particularly in high risk. An alternative to exogenous hCG is the administration of a GnRH agonist inducing an endogenous rise in both LH and FSH levels due to the initial flare effect. Comparisons: Pregnancy rates and embryological data will be compared from hyper-responding patients receiving either GnRH agonist (Arvekap) or hCG (Pregnyl) for ovulatrion induction following a GnRH antagonist treatment cycle.

Official Title
-----------------
Administration of Human Chorionic Gonadotropin (hCG) Versus Gonadotropin Releasing Hormone (GnRH) Agonist for Ovulation Induction in Hyper-Responder Patients

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Drug: Arvekap, Pregnyl


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hyper-responder patients (>20 oocytes retrieved) Exclusion Criteria: Normal responders Poor responders PCOS

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Arvekap, Pregnyl|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ongoing pregnancy per embryo transfer |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biochemical pregnancy per embryo transfer |  |  | 
| Clinical pregnancy per embryo transfer |  |  | 
| Embryological data |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ovulation induction, hCG, GnRH agonist, hyper-responders
Contribution of MRI in the Evaluation of Apparent Diffusion Coefficient and Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer

Study Overview
=================
Brief Summary
-----------------
The main objective of the study is to assess the sensitivity and the specificity of the variation of apparent diffusion coefficient for prediction, after a course of neoadjuvant chemotherapy or after modification of the treatment sequence, the pathological response at the end of chemotherapy

Official Title
-----------------
Etude ADC Apport de l'IRM Dans l'évaluation du Coefficient de Diffusion Apparent et prédiction de la réponse à la chimiothérapie néoadjuvante Dans le Cancer du Sein

Conditions
-----------------
Assess the Variation of Apparent Diffusion Coefficient

Intervention / Treatment
-----------------
* Other: MRI (Magnetic resonance imaging)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age> 18 years. Patient suffering from a breast tumor, regardless of the stage and size Patient requiring neoadjuvant chemotherapy Patient has the ability to undergo 18F-FDG-PET at baseline, at end of cycle 1 and at the end of neoadjuvant treatment before surgery Compulsory affiliation to a social security system. Obtaining informed consent in writing, signed and dated. Exclusion Criteria: Patient with cognitive or psychiatric disorders. Patient deprived of liberty by a court or administrative. Patient with signs against the achievement of MRI, mammography and ultrasound Patient metastatic Patient with prior chemotherapy, radiotherapy and hormone therapy for her breast cancer Pregnant women, current lactation Patient suffering from uncontrolled diabetes (> 11 mmol / L)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: MRI (Magnetic resonance imaging)|MRI will be realised at the beginning of the study, after a cycle of chemotherapy or at changement of sequence and at the end of chemotherapy.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Variation of apparent diffusion coefficient before / after a cycle of neoadjuvant chemotherapy or before / after modification of the treatment sequence and correlated with histologic response |  | One year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ADC, breast cancer, complete pathological response
Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence

Study Overview
=================
Brief Summary
-----------------
The reason for having a higher incidence of preeclampsia in primiparas may involve angiogenesis imbalance in these patients.

Detailed Description
-----------------
Primiparity is one of the main risk factors for having preeclampsia during pregnancy. Recently, sFlt-1, soluble FMS-like tyrosine kinase-1, has been shown to be a major molecule involved in the pathogenesis of preeclampsia. Higher sFlt-1 mRNA, higher serum levels of sFlt-1 as well as lower PlGF, placental growth factor, have been found in preeclamptic patients. We intend to check the angiogenesis profile of primiparas as compared to multiparas.

Official Title
-----------------
Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence

Conditions
-----------------
Pre-Eclampsia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Every delivery Exclusion Criteria: Preeclampsia or pregnancy induced hypertension
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
preeclampsia, sFlt1, PlGF, parity, angiogenesis